CoChat

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

Open access
Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian, Groop, Per-Henrik, on behalf of the EMPA-REG OUTCOME Investigators · 2018 · Journal of the American Society of Nephrology

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Abstract

Background: Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. Methods: Participants ( n =7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up). Results: Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m 2 ) decreased with empagliflozin (−0.77; 95% confidence interval, −0.83 to −0.71; placebo: 0.01; 95% confidence interval, −0.08 to 0.10; P <0.001). However, annual mean slope (ml/min per 1.73 m 2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: −1.46; 95% confidence interval, −1.74 to −1.17; P <0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m 2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo −0.02; 95% confidence interval, −0.12 to 0.08; P <0.001). Results were consistent across patient subgroups at higher CKD risk. Conclusions: The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2018010103

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 224

Metadata

Authors
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., Groop, P.-H., & on behalf of the EMPA-REG OUTCOME Investigators
Affiliations
  • Universitätsklinikum Würzburg (DE)
  • University Medical Center Groningen (NL)
  • Mount Sinai Hospital (CA)
  • Yale University (US)
  • Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany;
  • Boehringer Ingelheim (Germany) (DE)
  • Universität Ulm (DE)
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany;
  • University of Helsinki (FI)
Corresponding author
Wanner, Christoph
Venue
Journal of the American Society of Nephrology
Published
2018-10-12
Volume
29
Issue
11
Pages
2755-2769
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2897993744
Cited by
209
References
27
Citations by year
2026: 15 · 2025: 12 · 2024: 22 · 2023: 35 · 2022: 38 · 2021: 31 · 2020: 29 · 2019: 25 · 2018: 1
FWCI
17.63
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
American Society of Nephrology
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
empagliflozin, renal function decline, type 2 diabetes, estimated glomerular filtration rate, eGFR slope, chronic kidney disease, EMPA-REG OUTCOME trial, SGLT2 inhibitors, drug discontinuation, renal function recovery, hemodynamic effects, cardiovascular risk reduction
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glomerular Filtration Rate, Glucosides, Humans, Male, Middle Aged, Models, Statistical, Cohort Studies, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. https://app.cochat.ai/papers/10.1681/asn.2018010103
The paper
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., Groop, P.-H., & on behalf of the EMPA-REG OUTCOME Investigators. (2018). Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2018010103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.